LENZ Therapeutics, Inc. Q3 FY2026 earnings call

• Strategic Reorganization: Lenz Therapeutics announced a shift to a consumer-led commercial model, reducing the organization to approximately 40 employees. This restructuring aims to lower operating expenses by more than 50%, targeting $70–$75 million in annual spend for 2027, with over 70% allocated to consumer-driven marketing.
• Leadership Transition: CEO Evert Schimmelpennink will step down effective December 1, 2026, transitioning to a strategic advisor role. CFO Dan Chevallard will serve as interim CEO during the search for a permanent leader.
• Commercial Momentum: VIS (Viz) achieved over 50% growth in both product revenue and prescriptions in Q3. Awareness among eye care professionals (ECPs) exceeds 90%, with more than 15,000 prescribing ECPs, 75% of whom have prescribed multiple times.
• Channel Performance: The telehealth channel, launched in July, contributed more than 50% of incremental scripts in Q3. National TV advertising campaigns expanded reach, driving demand across retail, e-pharmacy, and telehealth channels.
• Market Leadership: Viz holds 94% market share in the U.S. presbyopia eye drop category since approval, having distributed over 4 million vials and sold approximately 110,000 packs through Q3.
• Global Expansion: There are 11 regulatory submissions under review globally, with expectations for multiple additional submissions and potential ex-US approvals in coming months.

The company reported total product revenues of $2.6 million for Q3 2026, representing a 50% sequential increase over Q2. This was driven by 38,000 paid scripts, marking a 51% sequential growth in prescriptions. Additionally, the company recognized $0.8 million in licensed revenue from Aerotex Pharmaceuticals. The gross-to-net ratio remained strong at approximately 93%, with cost of sales totaling $0.5 million. While specific percentage contribution of each segment to total revenue is not explicitly broken down beyond product vs. license, product revenue constitutes the primary operational metric discussed.

• Operating Expenses: Management targets 2027 annual operating expenses in the range of $70 to $75 million, reflecting a >50% reduction from prior levels.
• Cost Structure: Over 70% of projected 2027 spend will be allocated to consumer-driven sales and marketing strategies.
• Restructuring Costs: The company anticipates approximately $5 million in one-time net restructuring charges associated with the organizational reorganization, expected to be completed in Q4.
• Cash Position: As of Q3 end, the company held approximately $197.3 million in cash, cash equivalents, and marketable securities.
• No Revenue/Cash Runway Guidance: Management explicitly stated they are not providing specific revenue or cash runway guidance at this time.

• Forward-Looking Statements: Actual results may differ materially from projections due to various factors outlined in SEC filings.
• Execution Risk: The success of the new consumer-led model depends on effective execution of digital/TV advertising and telehealth integration.
• Regulatory Uncertainty: Global expansion relies on successful regulatory approvals in multiple jurisdictions, which face inherent delays and risks.
• Data Accuracy: Discrepancies between Symphony and IQVIA prescription data were noted, with management citing Symphony as more accurate but acknowledging potential variability.
• Market Adoption: Building a new category takes time; failure to sustain consumer demand generation could impact long-term growth trajectories.

Q: Analyst asked about telehealth's future contribution, confidence in continued growth, and correlation between prescriptions and DTC strategy. / A: Shawn Olsson confirmed telehealth drove significant Q3 growth and remains a key channel. He cited positive early KPIs like website traffic as confidence drivers. Regarding data alignment, he noted Symphony data is preferred for accuracy (~70%) over IQVIA, though exact correlations vary.

Q: Analyst requested details on telehealth patient profiles, specifically async vs. sync appointments and demographic characteristics. / A: Olsson explained most evaluations are asynchronous after initial risk screening. Demographically, telehealth patients mirror other channels (50/50 gender split), slightly skewing younger (45-55 age range). Screening effectively filters high-risk patients before doctor evaluation.

Q: Analyst inquired about the sales cycle speed via telehealth compared to traditional offices and if ex-US partners are adopting the US DTC model. / A: Olsson highlighted that telehealth reduced the ad-to-script cycle from weeks to days, allowing real-time tracking of ad efficacy. Dan Chevallard added that while ex-US partners leverage US learnings, they must adapt strategies to local market nuances rather than copying the US approach directly.

Q: Analyst questioned if growth outside telehealth relies on specific prescribers and if removing the field team impacts trajectory. / A: Olsson stated growth outside telehealth comes from broad adoption across 15,000+ ECPs, including non-targeted doctors driven by consumer demand. Confidence in removing reps stems from high awareness (90%) and repeat prescribing behavior triggered by patient inquiries rather than physician detailing.

Q: Analyst asked about refill rates and timeline to profitability following restructuring. / A: Olsson reported ~60% of e-pharmacy patients buy >1 month supply, with heavy users purchasing >5 packs/year. Dan Chevallard noted full expense reductions impact Q1 2027. No specific profitability date or cash runway guidance was provided, relying on the $197.3M cash position and reduced burn rate.